{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:50:16Z","timestamp":1785873016079,"version":"3.56.0"},"reference-count":203,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007284","name":"School of Medicine, Wayne State University","doi-asserted-by":"publisher","award":["T32-CA009531"],"award-info":[{"award-number":["T32-CA009531"]}],"id":[{"id":"10.13039\/100007284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R21CA270718-01A1"],"award-info":[{"award-number":["1R21CA270718-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA290480-01"],"award-info":[{"award-number":["1R01CA290480-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bcp.2026.118177","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:45:51Z","timestamp":1782143151000},"page":"118177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms"],"prefix":"10.1016","volume":"251","author":[{"given":"Kian K.","family":"Hershberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Thibodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Samanvitha","family":"Madagundapalli Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijendra","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118177_b0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.semcancer.2020.07.005","article-title":"Targeting p53 for the treatment of cancer","volume":"79","author":"Duffy","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2026.118177_b0010","article-title":"TP53 mutations in acute myeloid leukemia: still a daunting challenge?","volume":"10","author":"Molica","year":"2020","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0015","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv."},{"issue":"6453","key":"10.1016\/j.bcp.2026.118177_b0020","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hernandez Borrero","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0030","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1186\/s12864-015-1643-9","article-title":"Whole-genome cartography of p53 response elements ranked on transactivation potential","volume":"16","author":"Tebaldi","year":"2015","journal-title":"BMC Genomics"},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0035","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0040","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.cell.2011.03.035","article-title":"Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression","volume":"145","author":"Brady","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189326","article-title":"The multifunctional proline-rich domain of p53 tumor suppressor","volume":"1880","author":"Zhang","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"16","key":"10.1016\/j.bcp.2026.118177_b0050","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1093\/emboj\/17.16.4668","article-title":"The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression","volume":"17","author":"Venot","year":"1998","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0060","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41418-022-00980-7","article-title":"The genotypes and phenotypes of missense mutations in the proline domain of the p53 protein","volume":"29","author":"Hoyos","year":"2022","journal-title":"Cell Death Differ."},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045820","article-title":"p53 codon 72 polymorphism and hematological cancer risk: an update meta-analysis","volume":"7","author":"Weng","year":"2012","journal-title":"PLoS One"},{"issue":"38","key":"10.1016\/j.bcp.2026.118177_b0070","doi-asserted-by":"crossref","first-page":"e1588","DOI":"10.1097\/MD.0000000000001588","article-title":"The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: a PRISMA-Compliant Systematic Review and Meta-Analysis","volume":"94","author":"Ruan","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"12B","key":"10.1016\/j.bcp.2026.118177_b0075","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1101\/gad.7.12b.2556","article-title":"The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots","volume":"7","author":"Pavletich","year":"1993","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0080","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028308","article-title":"Structural evolution and dynamics of the p53 proteins","volume":"7","author":"Chillemi","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ng0492-45","article-title":"Definition of a consensus binding site for p53","volume":"1","author":"el-Deiry","year":"1992","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0090","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.molcel.2006.05.015","article-title":"Structural basis of DNA recognition by p53 tetramers","volume":"22","author":"Kitayner","year":"2006","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0095","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jmb.2004.06.071","article-title":"Cooperative binding of tetrameric p53 to DNA","volume":"341","author":"Weinberg","year":"2004","journal-title":"J. Mol. Biol."},{"issue":"17\u201318","key":"10.1016\/j.bcp.2026.118177_b0100","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1101\/gad.340976.120","article-title":"p53 tetramerization: at the center of the dominant-negative effect of mutant p53","volume":"34","author":"Gencel-Augusto","year":"2020","journal-title":"Genes Dev."},{"issue":"5170","key":"10.1016\/j.bcp.2026.118177_b0105","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations","volume":"265","author":"Cho","year":"1994","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0110","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0120","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41420-024-01940-5","article-title":"The epigenetic regulators EP300\/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia","volume":"10","author":"Wu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0125","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/s41418-024-01326-1","article-title":"Determinants of p53 DNA binding, gene regulation, and cell fate decisions","volume":"31","author":"Fischer","year":"2024","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.bcp.2026.118177_b0130","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026211","article-title":"Attenuating the p53 pathway in human cancers: many means to the same end","volume":"6","author":"Wasylishen","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0135","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cell.2009.04.050","article-title":"Modes of p53 regulation","volume":"137","author":"Kruse","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0140","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000950","article-title":"Posttranslational modification of p53: cooperative integrators of function","volume":"1","author":"Meek","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0145","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"p53 in survival, death and metabolic health: a lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6630","key":"10.1016\/j.bcp.2026.118177_b0155","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J. Biomed. Res."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0170","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2024.10.005","article-title":"Clonal hematopoiesis of indeterminate potential: the root cause of, and fertile ground for, hematological malignancies","volume":"31","author":"Zhuang","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOH.0000000000000509","article-title":"p53 involvement in clonal hematopoiesis of indeterminate potential","volume":"26","author":"Chen","year":"2019","journal-title":"Curr. Opin. Hematol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0180","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0185","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.stem.2008.11.006","article-title":"p53 regulates hematopoietic stem cell quiescence","volume":"4","author":"Liu","year":"2009","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0190","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.1038\/s41467-019-13542-2","article-title":"Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.bcp.2026.118177_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29245817","article-title":"Targeting EZH2 in cancer: mechanisms, pathways, and therapeutic potential","volume":"29","author":"Gilardini Montani","year":"2024","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0205","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-026-02526-w","article-title":"CDK4\/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis","volume":"58","author":"Chan","year":"2026","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2026.118177_b0210","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022;36(7):1703\u201319.","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0215","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0220","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118177_b0225","doi-asserted-by":"crossref","unstructured":"Hart SA, Lee LA, Seegmiller AC, Mason EF. Diagnosis of TP53-mutated myeloid disease by the ICC and WHO fifth edition classifications. Blood Adv. 2025;9(3):445\u201354.","DOI":"10.1182\/bloodadvances.2024014140"},{"issue":"15","key":"10.1016\/j.bcp.2026.118177_b0230","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bcp.2026.118177_b0235","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/bloodadvances.2023010312","article-title":"Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.bcp.2026.118177_b0240","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0245","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0250","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0255","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bcp.2026.118177_b0260","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2016.74","article-title":"High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS\/AML cohort","volume":"30","author":"Goel","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0265","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"issue":"18","key":"10.1016\/j.bcp.2026.118177_b0270","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1200\/JCO-24-02394","article-title":"Characterization and clinical implications of p53 dysfunction in patients with myelodysplastic syndromes","volume":"43","author":"Zampini","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0275","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0280","doi-asserted-by":"crossref","first-page":"8388","DOI":"10.18632\/oncotarget.3460","article-title":"Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes","volume":"6","author":"Devillier","year":"2015","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bcp.2026.118177_b0285","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/leu.2008.143","article-title":"Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype","volume":"22","author":"Haferlach","year":"2008","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.bcp.2026.118177_b0290","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0295","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical implications of subclonal TP53 mutations in acute myeloid leukemia","volume":"104","author":"Prochazka","year":"2019","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0300","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bcp.2026.118177_b0305","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood-2016-11-749903","article-title":"More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia","volume":"129","author":"Montalban-Bravo","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0310","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0315","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1600-0609.2000.90138.x","article-title":"Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia","volume":"65","author":"Nakano","year":"2000","journal-title":"Eur. J. Haematol."},{"issue":"23","key":"10.1016\/j.bcp.2026.118177_b0325","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1182\/blood-2010-01-266999","article-title":"Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia","volume":"116","author":"Parkin","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0330","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","article-title":"Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"34","author":"Herold","year":"2020","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.bcp.2026.118177_b0335","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0340","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41408-024-01077-9","article-title":"Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms","volume":"14","author":"Kaur","year":"2024","journal-title":"Blood Cancer J."},{"issue":"13","key":"10.1016\/j.bcp.2026.118177_b0345","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2022009100","article-title":"Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS","volume":"7","author":"Stengel","year":"2023","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0350","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/leu.2008.375","article-title":"The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia","volume":"23","author":"Seifert","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0355","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.bcp.2026.118177_b0360","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/bloodadvances.2024015238","article-title":"Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations","volume":"9","author":"Shah","year":"2025","journal-title":"Blood Adv."},{"issue":"13","key":"10.1016\/j.bcp.2026.118177_b0365","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/bloodadvances.2025016336","article-title":"Can we harmonize classification of TP53 mutant MDS\/AML?","volume":"9","author":"Sallman","year":"2025","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0370","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/jha2.791","article-title":"Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions","volume":"4","author":"Patel","year":"2023","journal-title":"Ejhaem"},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0375","first-page":"3533","article-title":"Prognostic impact of 'multi-hit' versus 'single-hit' TP53 alteration in patients with acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases","volume":"109","author":"Badar","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0380","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1007\/s00277-024-06054-7","article-title":"Overall survival in TP53-mutated AML and MDS","volume":"103","author":"Puzo","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0385","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","article-title":"TP53 mutation variant allele frequency of >\/=10% is associated with poor prognosis in therapy-related myeloid neoplasms","volume":"13","author":"Shah","year":"2023","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0390","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0395","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","article-title":"TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation","volume":"9","author":"Lontos","year":"2025","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0400","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/bloodadvances.2019001101","article-title":"Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes","volume":"4","author":"Montalban-Bravo","year":"2020","journal-title":"Blood Adv."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2026.118177_b0405","first-page":"15","article-title":"Genetic characteristics and outcomes by mutation status in a phase 3 Study of CPX-351 Versus 7+3 in older adults with newly Diagnosed, High-Risk\/Secondary Acute Myeloid Leukemia (AML)","volume":"134","author":"Lancet","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0410","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12185-016-1942-1","article-title":"TP53 mutations in older adults with acute myeloid leukemia","volume":"103","author":"Yanada","year":"2016","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0415","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-naive TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0420","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41375-019-0390-3","article-title":"Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically","volume":"33","author":"Mrozek","year":"2019","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.bcp.2026.118177_b0425","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0430","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118177_b0435","article-title":"Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: results from consortium on myeloid malignancies and neoplastic diseases (COMMAND)","volume":"140","author":"Talha Badar","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0440","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118177_b0445","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-8722-6-32","article-title":"Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group","volume":"6","author":"Pleyer","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0450","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-014-2126-9","article-title":"Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group","volume":"93","author":"Pleyer","year":"2014","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0455","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ajh.23654","article-title":"Azacitidine in untreated acute myeloid leukemia: a report on 149 patients","volume":"89","author":"Thepot","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.bcp.2026.118177_b0460","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0465","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1080\/10428194.2017.1422864","article-title":"Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia","volume":"59","author":"Boddu","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0470","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1038\/s41375-018-0257-z","article-title":"Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care","volume":"32","author":"Dohner","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0475","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.bcp.2026.118177_b0480","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2026.118177_b0485","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) 2023 [updated Acute Myeloid Leukemia. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0490","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118177_b0495","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv."},{"issue":"26","key":"10.1016\/j.bcp.2026.118177_b0500","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0505","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0510","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118177_b0515","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer."},{"issue":"15","key":"10.1016\/j.bcp.2026.118177_b0520","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0525","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi","year":"2016","journal-title":"Oncotarget."},{"issue":"17","key":"10.1016\/j.bcp.2026.118177_b0530","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0535","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.leukres.2014.03.012","article-title":"Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine","volume":"38","author":"Bally","year":"2014","journal-title":"Leuk Res."},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0540","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.3324\/haematol.2014.104760","article-title":"Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia","volume":"99","author":"Muller-Thomas","year":"2014","journal-title":"Haematologica."},{"issue":"27","key":"10.1016\/j.bcp.2026.118177_b0545","doi-asserted-by":"crossref","first-page":"19342","DOI":"10.18632\/oncotarget.25046","article-title":"Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine","volume":"9","author":"Cabezon","year":"2018","journal-title":"Oncotarget."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0550","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bjh.14455","article-title":"TP53 mutations predict decitabine-induced complete responses in patients with myelodysplastic syndromes","volume":"176","author":"Chang","year":"2017","journal-title":"Br J Haematol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0555","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10238-020-00641-4","article-title":"Role of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis","volume":"20","author":"Cai","year":"2020","journal-title":"Clin Exp Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0560","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3026(23)00338-1","article-title":"Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study","volume":"11","author":"Garcia-Manero","year":"2024","journal-title":"Lancet Haematol."},{"issue":"Supplement 1","key":"10.1016\/j.bcp.2026.118177_b0565","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1182\/blood-2022-163841","article-title":"Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine\/Cedazuridine in the Ascertain Trial (ASTX727-02)","volume":"140","author":"Savona","year":"2022","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.bcp.2026.118177_b0570","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0575","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0580","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1111\/bjh.16166","article-title":"Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia","volume":"187","author":"Aldoss","year":"2019","journal-title":"Br J Haematol."},{"issue":"20","key":"10.1016\/j.bcp.2026.118177_b0585","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.33689","article-title":"Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax","volume":"127","author":"Kim","year":"2021","journal-title":"Cancer."},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0590","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2026.118177_b0595","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2021-145613","article-title":"Molecular responses are observed across mutational spectrum in treatment-na\u00efve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine","volume":"138","author":"Garcia","year":"2021","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0600","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am J Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2026.118177_b0605","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2025-235","article-title":"Subgroup analyses from the randomized, phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-na\u00efve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)","volume":"146","author":"Garcia-Manero","year":"2025","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.bcp.2026.118177_b0610","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1080\/10428194.2022.2123228","article-title":"Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"63","author":"Shahzad","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2026.118177_b0615","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2018-99-116469","article-title":"Presence of TP53 mutation and monosomal karyotype predict the outcome of patients with acute myeloid leukemia in non-remission at allogeneic stem cell transplantation","volume":"132","author":"Najima","year":"2018","journal-title":"Blood."},{"issue":"28","key":"10.1016\/j.bcp.2026.118177_b0620","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1200\/JCO.23.00866","article-title":"Allogeneic hematopoietic cell transplantation improves outcome in myelodysplastic syndrome across high-risk genetic subgroups: genetic analysis of the blood and marrow transplant clinical trials network 1102 study","volume":"41","author":"Versluis","year":"2023","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0625","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.bcp.2026.118177_b0630","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0635","doi-asserted-by":"crossref","first-page":"E232","DOI":"10.1002\/ajh.26546","article-title":"Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival","volume":"97","author":"Badar","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0640","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41409-020-01016-9","article-title":"Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT","volume":"56","author":"Najima","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2026.118177_b0645","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1182\/blood-2024-210037","article-title":"Clonal Evolution of TP53 configurations with treatment predict prognosis in myeloid neoplasms","volume":"144","author":"Padmanabhan","year":"2024","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0650","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0655","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41375-022-01650-w","article-title":"Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603\/RATIFY trial","volume":"36","author":"Jahn","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.bcp.2026.118177_b0660","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.bcp.2026.118177_b0665","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0670","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2026.118177_b0675","article-title":"TP53 inactivation confers resistance to the menin inhibitor revumenib in acute myeloid leukemia","author":"D'Souza","year":"2025","journal-title":"bioRxiv"},{"issue":"26","key":"10.1016\/j.bcp.2026.118177_b0680","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/blood.2023020731","article-title":"The role of the MDM2\/p53 axis in antitumor immune responses","volume":"143","author":"Brummer","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0685","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020442","article-title":"Essential roles of E3 ubiquitin ligases in p53 regulation","volume":"18","author":"Sane","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.bcp.2026.118177_b0690","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1039\/D5SC00120J","article-title":"Affinity-based protein profiling of MDM2 inhibitor Navtemadlin","volume":"16","author":"Date","year":"2025","journal-title":"Chem. Sci."},{"issue":"36","key":"10.1016\/j.bcp.2026.118177_b0695","doi-asserted-by":"crossref","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy","volume":"110","author":"Chang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"14","key":"10.1016\/j.bcp.2026.118177_b0700","doi-asserted-by":"crossref","first-page":"9401","DOI":"10.1021\/acs.jmedchem.3c00623","article-title":"Discovery of sulanemadlin (ALRN-6924), the first cell-permeating, stabilized alpha-helical peptide in clinical development","volume":"66","author":"Guerlavais","year":"2023","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0705","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12113638","article-title":"MDM2 Implications for potential molecular pathogenic therapies of soft-tissue tumors","volume":"12","author":"Sun","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2026.118177_b0710","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fonc.2016.00007","article-title":"Clinical overview of MDM2\/X-targeted therapies","volume":"6","author":"Burgess","year":"2016","journal-title":"Frontiers in Oncology."},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0715","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1078-0432.CCR-14-2300","article-title":"Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia","volume":"21","author":"Richmond","year":"2015","journal-title":"Clinical Cancer Research : an Official Journal of the American Association for Cancer Research."},{"issue":"14","key":"10.1016\/j.bcp.2026.118177_b0720","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm400487c","article-title":"Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development","volume":"56","author":"Ding","year":"2013","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0725","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1535-7163.MCT-14-0710","article-title":"The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the activity of p53-Inducing Cytotoxic Agents","volume":"14","author":"Canon","year":"2015","journal-title":"Molecular Cancer Therapeutics."},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0730","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1021\/acs.jmedchem.6b01665","volume":"60","author":"Aguilar","year":"2017","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118177_b0735","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1158\/1535-7163.MCT-24-0306","article-title":"KT-253, a Novel MDM2 degrader and p53 stabilizer, has superior potency and efficacy than MDM2 small-molecule inhibitors","volume":"24","author":"Chutake","year":"2025","journal-title":"Molecular Cancer Therapeutics."},{"issue":"13","key":"10.1016\/j.bcp.2026.118177_b0740","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2217\/fon-2020-0044","article-title":"MIRROS: a randomized, placebo-controlled, phase III trial of cytarabine +\/- idasanutlin in relapsed or refractory acute myeloid leukemia","volume":"16","author":"Montesinos","year":"2020","journal-title":"Future Oncology."},{"issue":"13","key":"10.1016\/j.bcp.2026.118177_b0745","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1182\/bloodadvances.2019030916","article-title":"Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed\/refractory acute myeloid leukemia","volume":"3","author":"Erba","year":"2019","journal-title":"Blood Advances"},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0750","doi-asserted-by":"crossref","first-page":"9645","DOI":"10.1021\/acs.jmedchem.4c00784","article-title":"Discovery of Novel p53-MDM2 Inhibitor (RG7388)-conjugated platinum(IV) complexes as potent antitumor agents","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0755","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acs.molpharmaceut.3c00926","article-title":"Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC inhibitor entinostat enhances their therapeutic potential through synergistic antitumor effects and reduction of systemic toxicity","volume":"21","author":"Abed","year":"2024","journal-title":"Molecular Pharmaceutics"},{"issue":"24","key":"10.1016\/j.bcp.2026.118177_b0760","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0765","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1756-8722-6-74","article-title":"The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies","volume":"6","author":"Shi","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0770","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3724\/abbs.2025071","article-title":"CD47-mediated tumor microenvironment remodeling: a central mechanism in immune evasion","volume":"57","author":"Yuan","year":"2025","journal-title":"Acta Biochimica et Biophysica Sinica."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0775","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","article-title":"Role of CD47 in hematological malignancies","volume":"13","author":"Eladl","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0780","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3324\/haematol.2023.283154","article-title":"CD47 expression in acute myeloid leukemia varies according to genotype","volume":"108","author":"Marra","year":"2023","journal-title":"Haematologica"},{"issue":"6282","key":"10.1016\/j.bcp.2026.118177_b0785","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science (New York, NY)"},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0790","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1128\/MCB.18.7.3735","article-title":"Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain","volume":"18","author":"Frazier","year":"1998","journal-title":"Mole. Cellular Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0795","first-page":"7805","article-title":"Transactivation of the human p53 tumor suppressor gene by c-Myc\/Max contributes to elevated mutant p53 expression in some tumors","volume":"14","author":"Roy","year":"1994","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.molcel.2017.11.006","article-title":"Mutant p53 gains its function via c-Myc activation upon CDK4 phosphorylation at serine 249 and consequent PIN1 binding","volume":"68","author":"Liao","year":"2017","journal-title":"Molecular Cell."},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0805","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood.2025029850","article-title":"Magrolimab and the tale of indigestible AML","volume":"146","author":"R\u00f6llig","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0810","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3390\/cancers17091509","article-title":"Magrolimab Therapy in Conjunction with conventional chemotherapeutics slows disease progression in pediatric acute myeloid leukemia patient-derived xenograft models","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers."},{"issue":"31","key":"10.1016\/j.bcp.2026.118177_b0815","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1200\/JCO.22.02604","article-title":"Tolerability and efficacy of the anticluster of differentiation 47 antibody magrolimab combined with azacitidine in patients with previously untreated AML: phase Ib results","volume":"41","author":"Daver","year":"2023","journal-title":"J. Clin. Oncol.: Off. J. American Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0820","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-023-01411-x","article-title":"Novel agents and regimens in acute myeloid leukemia: latest updates from 2022 ASH annual meeting","volume":"16","author":"DiNardo","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0825","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MOH.0000000000000691","article-title":"Targeting the cluster of differentiation 47\/signal-regulatory protein alpha axis in myeloid malignancies","volume":"29","author":"Wang","year":"2022","journal-title":"Curr. Opin. Hematol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0830","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"issue":"6794","key":"10.1016\/j.bcp.2026.118177_b0835","doi-asserted-by":"crossref","DOI":"10.1126\/science.ady5196","article-title":"Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity","volume":"392","author":"Chung","year":"2026","journal-title":"Science."},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0840","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005517","article-title":"Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity","volume":"10","author":"Qu","year":"2022","journal-title":"J. Immunotherapy Cancer"},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0845","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/trf.18367","article-title":"Anti-CD47 drug interference in pre-transfusion testing can be overcome by antigen masking","volume":"65","author":"Habicht","year":"2025","journal-title":"Transfusion."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0850","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12967-023-04710-6","article-title":"Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile","volume":"22","author":"Wang","year":"2024","journal-title":"J. Translational Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2026.118177_b0855","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2021-153683","article-title":"CD47-Blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcp.2026.118177_b0860","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201832","article-title":"ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile","volume":"13","author":"Kauder","year":"2018","journal-title":"PloS One"},{"issue":"Suppl. 16","key":"10.1016\/j.bcp.2026.118177_b0865","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1200\/JCO.2024.42.16_suppl.6510","article-title":"Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS)","volume":"42","author":"Yang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0870","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113087","article-title":"CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies","volume":"12","author":"El Achi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0875","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-021-01163-6","article-title":"SIRP\u03b1-\u03b1CD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells","volume":"14","author":"Tahk","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0880","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0885","first-page":"411","article-title":"PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53","volume":"30","author":"Zache","year":"2008","journal-title":"Cell Oncol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0890","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118177_b0895","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0900","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bjh.14036","article-title":"Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2\/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells","volume":"174","author":"Ali","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2026.118177_b0905","doi-asserted-by":"crossref","first-page":"14844","DOI":"10.1038\/ncomms14844","article-title":"Inhibiting the system x(C)(-)\/glutathione axis selectively targets cancers with mutant-p53 accumulation","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bcp.2026.118177_b0910","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1535-7163.MCT-21-0067","article-title":"SLC7A11 is a superior determinant of APR-246 (Eprenetapopt) response than TP53 mutation status","volume":"20","author":"Fujihara","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"14","key":"10.1016\/j.bcp.2026.118177_b0915","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118177_b0920","unstructured":"A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination With Azacitidine Versus Azacitidine Alone for the Treatment of (Tumor Protein) TP53 Mutant Myelodysplastic Syndromes [Internet]. 2018. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03745716."},{"issue":"18","key":"10.1016\/j.bcp.2026.118177_b0925","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1182\/blood.2025028803","article-title":"XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies","volume":"146","author":"Kruer","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0930","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJMoa2508820","article-title":"Phase 1 study of rezatapopt, a p53 reactivator, in TP53 Y220C-mutated Tumors","volume":"394","author":"Dumbrava","year":"2026","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0935","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bcp.2026.118177_b0940","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118177_b0945","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b0950","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2026.118177_b0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136855","article-title":"Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated results from a phase 1b Study","volume":"136","author":"Brunner","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118177_b0960","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(23)00333-2","article-title":"Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"11","author":"Zeidan","year":"2024","journal-title":"Lancet Haematol."},{"issue":"20","key":"10.1016\/j.bcp.2026.118177_b0965","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.bcp.2026.118177_b0970","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/ncb3427","article-title":"DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway","volume":"18","author":"Parrales","year":"2016","journal-title":"Nat Cell Biol."},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b0975","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/cdd.2011.71","article-title":"SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis","volume":"18","author":"Li","year":"2011","journal-title":"Cell Death Differ."},{"issue":"21","key":"10.1016\/j.bcp.2026.118177_b0980","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1158\/1078-0432.CCR-17-1423","article-title":"Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature","volume":"23","author":"Craddock","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118177_b0985","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccell.2020.11.013","article-title":"Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bcp.2026.118177_b0990","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2011.59","article-title":"The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome","volume":"25","author":"Burnett","year":"2011","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.bcp.2026.118177_b0995","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/cncr.34780","article-title":"Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: a phase 2 substudy of the beat AML master trial","volume":"129","author":"Duong","year":"2023","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.118177_b1000","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bcp.2026.118177_b1005","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2024027117","article-title":"Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.bcp.2026.118177_b1010","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1182\/blood.2024025834","article-title":"A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort","volume":"144","author":"Goldfinger","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118177_b1015","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2026.300534","article-title":"Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax","author":"Goldfinger","year":"2026","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bcp.2026.118177_b0055","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1535-6108(03)00272-1","article-title":"Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription","volume":"4","author":"Chipuk","year":"2003","journal-title":"Cancer Cell"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226005162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:42:08Z","timestamp":1785872528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226005162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":203,"alternative-id":["S0006295226005162"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118177","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118177"}}